Empagliflozin confers reno ‐protection in acute myocardial infarction and type 2 diabetes mellitus

ConclusionsEmpagliflozin prevented the kidney functional decline in patients with AMI and T2DM, especially those with baseline eGFR  ≥ 60 mL/min/1.73 m2. Early administration of sodium –glucose cotransporter 2 inhibitors in these patients is considered desirable for renal protection.

Source: ESC Heart Failure - July 8, 2021 Category: Cardiology Authors: Kosuke Mozawa, Yoshiaki Kubota, Yu Hoshika, Shuhei Tara, Yukichi Tokita, Kenji Yodogawa, Yu ‐ki Iwasaki, Takeshi Yamamoto, Hitoshi Takano, Yayoi Tsukada, Kuniya Asai, Masaaki Miyamoto, Yasushi Miyauchi, Eitaro Kodani, Mitsunori Maruyama, Tags: Original Research Article Source Type: research